



ASX ANNOUNCEMENT

29 April 2016

Cynata and Regience Extend Entitlement Period

- Regience remains committed to the proposed strategic alliance
- Investment entitlement period extended to 4 July 2016
- Initial investment increased to \$400,000

Melbourne, Australia; 29 April 2016: Australian stem cell and regenerative medicine company, [Cynata Therapeutics Ltd](#) (ASX: CYP), has agreed to a request from Regience K.K. to extend the 60-day entitlement period to make an initial investment in new ordinary shares issued by Cynata. The extension will provide a period for Regience to make the initial investment on or before 4 July 2016. Details of the proposed strategic alliance between Regience and Cynata are set out in the announcement issued by the Company on 3 March 2016.

In consideration for Cynata agreeing to the extension, the initial investment has been increased from A\$250,000 to A\$400,000, under the same terms per the aforementioned 3 March 2016 announcement.

“Cynata’s project is the top priority for us and our commitment to commercialise in Japan remains unchanged if not even more enthusiastic,” said Mr Masanori Murayama, CEO of Regience. The extension provides further time for Regience to complete certain financing activities given the interruption caused by the traditional Golden Week holiday period in Japan.

CONTACTS: Dr Ross Macdonald, CEO: Tel: 0412 119343; email ross.macdonald@cynata.com
Dr Stewart Washer, Executive Chairman: Tel: 0418 288212; email stewart.washer@cynata.com
Kirin Smith, Chief Operations Officer, Investor Contact, +1 646-863-6519, ksmith@pcgadvisory.com
Sean Leous, Chief Communications Officer, Media Contact, +1 646-863-8998, sleous@pcgadvisory.com
Rudi Michelson, Monsoon, Australia Media Contact, 0411 402 737, rudim@monsoon.com.au

About Cynata Therapeutics (ASX: CYP)

Cynata Therapeutics Limited (ASX: CYP) is an Australian stem cell and regenerative medicine company that is developing a therapeutic stem cell platform technology, Cymerus™, originating from the University of Wisconsin-Madison, a world leader in stem cell research. The proprietary Cymerus™ technology addresses a critical shortcoming in existing methods of production of mesenchymal stem cells (MSCs) for therapeutic use, which is the ability to achieve economic manufacture at commercial scale. Cymerus™ does so through the production of a particular type of MSC precursor, called a mesenchymoangioblast (MCA). The Cymerus™ MCA platform provides a source of MSCs that is independent of donor limitations and provides a potential “off-the-shelf” stem cell platform for therapeutic product use, with a pharmaceutical business model and economies of scale. This has the potential to create a new standard in the emergent arena of stem cell therapeutics and provides both a unique differentiator and an important competitive position.

Cynata Therapeutics Limited

Suite 1, 1233 High Street, Armadale, Victoria 3143, Australia
PO Box 7165, Hawthorn North, Victoria 3122
T: + 613 9824 5254 F: + 613 9822 7735 E: admin@cynata.com
ABN - 98 104 037 372